Upstream Bio (UPB) Projected to Post Earnings on Thursday

by · The Markets Daily

Upstream Bio (NASDAQ:UPB – Get Free Report) is projected to post its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Upstream Bio to post earnings of ($0.77) per share and revenue of $0.6460 million for the quarter. Individuals can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, November 6, 2025 at 7:00 AM ET.

Upstream Bio (NASDAQ:UPB – Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.13). Upstream Bio had a negative return on equity of 35.90% and a negative net margin of 3,836.58%.The business had revenue of $0.94 million during the quarter, compared to the consensus estimate of $0.32 million. On average, analysts expect Upstream Bio to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Upstream Bio Price Performance

UPB stock opened at $24.19 on Thursday. Upstream Bio has a 1-year low of $5.14 and a 1-year high of $29.46. The company has a market capitalization of $1.30 billion and a price-to-earnings ratio of -2.95. The business has a 50 day simple moving average of $19.01 and a two-hundred day simple moving average of $14.02.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Bank of America Corp DE grew its holdings in shares of Upstream Bio by 71.2% in the second quarter. Bank of America Corp DE now owns 18,031 shares of the company’s stock valued at $198,000 after purchasing an additional 7,500 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Upstream Bio by 85.4% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,084 shares of the company’s stock valued at $210,000 after purchasing an additional 8,788 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of Upstream Bio by 260.7% in the second quarter. Rhumbline Advisers now owns 48,066 shares of the company’s stock valued at $528,000 after purchasing an additional 34,739 shares in the last quarter. Woodline Partners LP grew its holdings in shares of Upstream Bio by 5.8% in the first quarter. Woodline Partners LP now owns 557,063 shares of the company’s stock valued at $3,409,000 after purchasing an additional 30,552 shares in the last quarter. Finally, American Century Companies Inc. purchased a new position in shares of Upstream Bio in the second quarter valued at $246,000.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Truist Financial assumed coverage on Upstream Bio in a research note on Tuesday, October 14th. They issued a “buy” rating and a $47.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Upstream Bio in a research note on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $53.33.

Get Our Latest Report on UPB

Upstream Bio Company Profile

(Get Free Report)

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.

Further Reading